TABLE 1.

Selection criteria for active surveillance based on different protocols currently used worldwide

PSA: prostate-specific antigen, ^a: and <50% of cancer in any core, ^b: for patients over age 70, these criteria were relaxed to include Gleason ≥7 (3+4) and/or ≤PSA 15 ng/ml, ^c: age 50-80 years